Ciencias Químicas
Facultad
Fundación Hospital Alcorcón
Alcorcón, EspañaPublicaciones en colaboración con investigadores/as de Fundación Hospital Alcorcón (17)
2023
-
Anaphylaxis to European Perch (Perca fluviatilis) Due to a-Actin Protein
Journal of investigational allergology & clinical immunology, Vol. 33, Núm. 2, pp. 143-144
2022
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
-
Seroreactivity Against Tyrosine Phosphatase PTPRN Links Type 2 Diabetes and Colorectal Cancer and Identifies a Potential Diagnostic and Therapeutic Target
Diabetes, Vol. 71, Núm. 3, pp. 497-510
2020
-
Outcomes of an enhanced recovery after radical cystectomy program in a prospective multicenter study: compliance and key components for success
World Journal of Urology, Vol. 38, Núm. 12, pp. 3121-3129
2016
-
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400
2014
-
A restricted population of CB1 cannabinoid receptors with neuroprotective activity
Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262
2013
-
Feasibility and safety of hospital discharge 24 hours after laparoscopic radical prostatectomy
Archivos Espanoles de Urologia, Vol. 66, Núm. 10, pp. 931-938
-
Resultados oncológicos en pacientes potencialmente candidatos a vigilancia activa sometidos a prostatectomía radical
Actas Urologicas Espanolas, Vol. 37, Núm. 10, pp. 603-607
-
Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour
BJU International, Vol. 111, Núm. 4 B
2011
-
GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized clinical trial with 2-year follow-up
European Urology, Vol. 60, Núm. 4, pp. 734-739
-
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease
Brain, Vol. 134, Núm. 1, pp. 119-136
-
Prospects for cannabinoid therapies in basal ganglia disorders
British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378
2010
-
Differences among pollen-allergic patients with and without plant food allergy
International Archives of Allergy and Immunology, Vol. 153, Núm. 2, pp. 182-192
2009
-
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Brain, Vol. 132, Núm. 11, pp. 3152-3164
2008
-
The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis
Journal of Biological Chemistry, Vol. 283, Núm. 19, pp. 13320-13324
-
The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccines
Journal of Allergy and Clinical Immunology, Vol. 122, Núm. 5
2007
-
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Trends in Pharmacological Sciences, Vol. 28, Núm. 1, pp. 39-45